» Articles » PMID: 27726415

The Emerging Role of MRI in Prostate Cancer Active Surveillance and Ongoing Challenges

Overview
Specialties Oncology
Radiology
Date 2016 Oct 12
PMID 27726415
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Active surveillance (AS) has emerged as a management strategy for preventing overtreatment of indolent prostate cancer. Selection of patients for AS has traditionally proved challenging and resulted in 20-30% misclassification rates. MRI has potential to help overcome this limitation, broaden selection criteria to increase recruitment, and minimize the invasive nature of AS follow-up.

Conclusion: The main issues surrounding MRI and AS are the heterogeneity of inclusion criteria, the definition of significant disease, and agreement about what constitutes radiologic progression. Prospective cohorts with MRI at enrollment and long-term follow-up are required to further address these issues.

Citing Articles

[Ga]Ga‑PSMA‑617 PET-based radiomics model to identify candidates for active surveillance amongst patients with GGG 1-2 prostate cancer at biopsy.

Yang J, Xiao L, Zhou M, Li Y, Cai Y, Gan Y Cancer Imaging. 2024; 24(1):86.

PMID: 38965552 PMC: 11229016. DOI: 10.1186/s40644-024-00735-2.


Stability of Multi-Parametric Prostate MRI Radiomic Features to Variations in Segmentation.

Thulasi Seetha S, Garanzini E, Tenconi C, Marenghi C, Avuzzi B, Catanzaro M J Pers Med. 2023; 13(7).

PMID: 37511785 PMC: 10381192. DOI: 10.3390/jpm13071172.


Prospective Implementation and Early Outcomes of a Risk-stratified Prostate Cancer Active Surveillance Follow-up Protocol.

Thankapannair V, Keates A, Barrett T, Gnanapragasam V Eur Urol Open Sci. 2023; 49:15-22.

PMID: 36874604 PMC: 9975013. DOI: 10.1016/j.euros.2022.12.013.


Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.

Sushentsev N, Rundo L, Abrego L, Li Z, Nazarenko T, Warren A Eur Radiol. 2023; 33(6):3792-3800.

PMID: 36749370 PMC: 10182165. DOI: 10.1007/s00330-023-09438-x.


Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction.

Lin Y, Liu G, Liu C, Xie H, Wang X, Huang Y Cancer Med. 2022; 11(15):2875-2885.

PMID: 35289508 PMC: 9359874. DOI: 10.1002/cam4.4629.